ApoE and immunity in Alzheimer's disease and related tauopathies: Low-density lipoprotein receptor to the rescue

Andrew S Mendiola; Reshmi Tognatta; Zhaoqi Yan; Katerina Akassoglou

doi:10.1016/j.neuron.2021.07.013

ApoE and immunity in Alzheimer's disease and related tauopathies: Low-density lipoprotein receptor to the rescue

Neuron. 2021 Aug 4;109(15):2363-2365. doi: 10.1016/j.neuron.2021.07.013.

Authors

Andrew S Mendiola¹, Reshmi Tognatta¹, Zhaoqi Yan¹, Katerina Akassoglou²

Affiliations

¹ Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.
² Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA 94158, USA; Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: kakassoglou@gladstone.ucsf.edu.

Abstract

In this issue of Neuron, Shi et al. (2021) show a protective role for the low-density lipoprotein receptor (LDLR) in tau pathology. Brain overexpression of LDLR lowers apolipoprotein E (apoE), suppresses microglial activation, preserves myelin, and ameliorates neurodegeneration, pointing the way toward potential new therapies.

Publication types

Comment

MeSH terms

Alzheimer Disease* / genetics
Apolipoproteins E / genetics
Brain / metabolism
Humans
Lipoproteins, LDL
Receptors, LDL / genetics
Receptors, LDL / metabolism
Tauopathies* / genetics

Substances

Apolipoproteins E
Lipoproteins, LDL
Receptors, LDL

Abstract

Publication types

MeSH terms

Substances

Grants and funding